• TRADE NAMES: Clexane (Sanofi-Aventis); Klexane; Lovenox (Sanofi-Aventis)
  • INDICATIONS: Prevention of deep vein thrombosis, ischemic complications of unstable angina and non-Q wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction
  • CLASS: Heparin, low molecular weight
  • HALF-LIFE: 4.5 hours

Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture.

Contra-indicated in patients with active major bleeding; thrombocytopenia with a positive in vitro test for anti-platelet antibody in the presence of enoxaparin; hypersensitivity to heparin or pork products; hypersensitivity to benzyl alcohol (multi-dose formulation only).

SPINAL/EPIDURAL HEMATOMA

See full prescribing information for complete boxed warning.

Please login to view the rest of this drug profile.

    DRUG REVIEW ARTICLE

    Click on the DRUG REVIEW ARTICLE tab (above) to see a review of enoxaparin in the Taylor & Francis journal Expert Opinion on Drug Safety.

    (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 04/19/2024

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric